European Companies Search Engine
EU funding (€11M): ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND) Hor1 Jan 2019 EU Research and Innovation programme "Horizon"
Overview
Text
ERA-NET to support the Joint Programming in Neurodegenerative Diseases strategic plan (JPND)
Worldwide, nearly 47 million people are currently estimated to be living with dementia, and the number is expected to almost double every 20 years, yet treatments that prevent or stop the progression of neurodegeneration are still lacking. Tackling this grand challenge requires enhanced coordination of national efforts to accelerate discovery. Such synergies have been created among 30 countries in the pilot EU JPI on Neurodegenerative Disease Research (JPND). JPND has a long standing experience in collaborative actions; since 2011, a cumulated funding of 132M€ has been dedicated to competitive transnational calls and JPND is now a reference for European and global knowledge and as an innovation platform in the area of neurodegenerative diseases. Building on earlier successes of the JPND Research Strategy in scaling-up and establishing synergies with Horizon 2020, there is a need to continue previous efforts to consolidate the JPND successes in defragmentation, better coordination and alignment amongst the countries, by developing new links with the EC. JPcofuND 2 aims at launching in 2019 an ambitious call for proposals on personalised medicine, where the benefits for the patients affected with neurodegenerative diseases will be explored through personalised diagnosis, personalised prevention and personalised care. Participating countries have earmarked 24,7 M€ of national funds for this call. Moreover, to expand the impact of the project, JPND will continue to implement other actions without EU co-funding such as aligning national research strategies, making databases more accessible and interoperable, developing enabling capacities such as supportive infrastructure and platforms, capacity building, education and training. These actions are required in parallel to achieve the highest impact for the patients, their carers and for society as whole and address this grand challenge in the coming years.
Funded Companies:
Source: https://cordis.europa.eu/project/id/825664
The filing refers to a past date, and does not necessarily reflect the current state.
